|
|
Summary ToggleOpiant Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update
|
|
|
|
Summary ToggleOpiant Pharmaceuticals to Report First Quarter 2019 Financial Results and Host Conference Call and Webcast on Thursday, May 9
|
|
|
|
Summary ToggleOpiant Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Data Supporting Potential of OPNT003, Nasal Nalmefene, for Treatment of Synthetic Opioid Overdose
|
|
|
|
Summary ToggleOpiant Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Data Supporting Potential of OPNT002, Nasal Naltrexone, for Treatment of Alcohol Use Disorder
|
|
|
|
Summary ToggleOpiant Pharmaceuticals Announces Award of Second Tranche of Approximately $3.0 Million from National Institutes of Health Grant for Development of OPNT003, Nasal Nalmefene, for Treatment of Opioid Overdose
|
|
|
|
Summary ToggleOpiant Pharmaceuticals to Present at 18th Annual Needham Healthcare Conference
|
|
|
|
Summary ToggleOpiant Pharmaceuticals, Inc. Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update
|
|
|
|
Summary ToggleOpiant Pharmaceuticals to Report Fiscal 2018 Financial Results and Host Conference Call and Webcast on Thursday, March 21
|
|
|
|
Summary ToggleOpiant Pharmaceuticals Announces Top-line Results from Phase 2 Clinical Trial of OPNT001 for Treatment of Bulimia Nervosa
|
|
